Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases

Respirology

Volumn 7, Issue 1, 2002, Pages 15-21

  Kuwano, Kazuyoshi ^a   Maeyama, Takashige ^a   Inoshima, Ichiro ^a   Ninomiya, Kiyoshi ^b   Hagimoto, Naoki ^a   Yoshimi, Michihiro ^a   Fujita, Masaki ^a   Nakamura, Norio ^c   Shirakawa, Kamon ^d   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^c R and D Department   (Japan)

^d MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Apoptosis; Fas; Fas ligand; Pulmonary fibrosis

Indexed keywords

CORTICOSTEROID; FAS ANTIGEN; FAS LIGAND; GLYCOPROTEIN; LACTATE DEHYDROGENASE; PROTEIN KL 6; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COLLAGEN DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS CELL TYPE 2; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

EID: 0036335052     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1843.2002.00369.x     Document Type: Article

References (29)

1. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
2. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
3. Expression of the Fas ligand in cells of T cell lineage
4. Cytotoxic-T cell cytotoxicity is mediated through perforin and Fas lytic pathways
5. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity
6. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
7. Metalloproteinase-mediated release of human Fas ligand
8. Expression of the functional soluble form of Fas ligand in activated lymphocytes
9. Fas ligand in human serum
10. Definition and classification of interstitial pneumonias in human pathology
11. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects
12. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases
13. New serum indicator of interstitial pneumonitis activity: Sialylated carbohydrate antigen KL-6
14. Monitoring of serum KL-6 antigen in patients with radiation pneumonia
15. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis
16. Pulmonary surfactant protein-D in sera and bronchoalveolar lavage fluids
17. Serum surfactant protein A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent
18. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement
19. Standardization of spirometry-1994 update
20. Single-breath carbon monoxide diffusing capacity (transfer factor): Recommendations for a standard technique-1995 update
21. The soluble form of Fas and Fas ligand in bronchoalveolar lavage fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia
22. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis
23. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids
24. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis
25. NF-κB-dependent Fas ligand expression
26. NF-κB antiapoptosis. Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
27. Inhibition of NF-κB activity induces apoptosis in murine hepatocytes
28. NF-κB determines localization and features of cell death in epidermis
29. Essential roles of the Fas-Fas-ligand pathway in pulmonary fibrosis